Patents Assigned to VIRACTA THERAPEUTICS, INC.
  • PYRIMIDINYL TYROSINE KINASE INHIBITORS
    Publication number: 20230174511
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton’s tyrosine kinase and which exhibit desirable characteristics for the same.
    Type: Application
    Filed: August 8, 2022
    Publication date: June 8, 2023
    Applicants: Viracta Therapeutics, Inc., Biogen MA Inc., Biogen MA Inc.
    Inventors: Brian T. HOPKINS, Timothy R. CHAN, Tracy J. JENKINS, Patrick CONLON, Xiongwei CAI, Michael HUMORA, Xianglin SHI, Ross A. MILLER, Andrew THOMPSON
  • METHODS AND COMPOSITIONS FOR TREATING VIRAL OR VIRALLY-INDUCED CONDITIONS
    Publication number: 20220249477
    Abstract: Provided are methods and compositions for the prevention and/or treatment of viral conditions, virally-induced conditions and inflammatory conditions. The methods can comprise administering to a subject a viral inducing agent with an antiviral agent, and optionally an additional agent. The viral inducing agent can be a HDAC inhibitor administered orally.
    Type: Application
    Filed: December 8, 2021
    Publication date: August 11, 2022
    Applicants: VIRACTA THERAPEUTICS, INC., TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Ronald J. Berenson, Douglas V. Faller
  • Methods of treating virally associated cancers with histone deacetylase inhibitors
    Patent number: 10953011
    Abstract: Described herein are certain dosing schedules and amounts that effectively prevent and manage side effects associated with histone deacetylase inhibitor (HDACi) treatment. Optionally, these schedules and dosing regimens include treatment with an antiviral agent.
    Type: Grant
    Filed: July 8, 2020
    Date of Patent: March 23, 2021
    Assignee: VIRACTA THERAPEUTICS INC.
    Inventors: Robert McRae, Gail L. Brown, Xiaohu Deng, David Slack, Marshelle Smith Warren, Richard Trauger
  • Methods and compositions for treating viral or virally-induced conditions
    Patent number: 10857152
    Abstract: Provided are methods and compositions for the prevention and/or treatment of viral conditions, virally-induced conditions and inflammatory conditions. The methods can comprise administering to a subject a viral inducing agent with an antiviral agent, and optionally an additional agent. The viral inducing agent can be a HDAC inhibitor administered orally.
    Type: Grant
    Filed: April 23, 2018
    Date of Patent: December 8, 2020
    Assignees: TRUSTEES OF BOSTON UNIVERSITY, VIRACTA THERAPEUTICS, INC.
    Inventors: Ronald J. Berenson, Douglas V. Faller
  • HISTONE DEACETYLASE INHIBITORS FOR USE IN IMMUNOTHERAPY
    Publication number: 20190216818
    Abstract: Provided are methods and compositions for the treatment of cancer. The methods comprise administering to a subject an HDAC inhibitor and an immunotherapeutic. In certain instances the immunotherapeutic is a chimeric antigen receptor T cell, an antibody or polypeptide that binds a checkpoint inhibitor, or a vaccine.
    Type: Application
    Filed: July 14, 2017
    Publication date: July 18, 2019
    Applicant: Viracta Therapeutics, Inc.
    Inventor: James N. WOODY
  • METHODS AND COMPOSITIONS FOR TREATING VIRAL OR VIRALLY-INDUCED CONDITIONS
    Publication number: 20190091221
    Abstract: Provided are methods and compositions for the prevention and/or treatment of viral conditions, virally-induced conditions and inflammatory conditions. The methods can comprise administering to a subject a viral inducing agent with an antiviral agent, and optionally an additional agent. The viral inducing agent can be a HDAC inhibitor administered orally.
    Type: Application
    Filed: April 23, 2018
    Publication date: March 28, 2019
    Applicants: VIRACTA THERAPEUTICS, INC., TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Ronald J. Berenson, Douglas V. Faller